Requires pharmacy benefits managers to make certain disclosures to health benefits plan sponsors.
Senate Bill 4206 would require pharmacy benefits managers (PBMs) to provide detailed, recurring disclosures to health benefits plan sponsors and to the Department of Banking and Insurance. The bill is aimed at increasing transparency in prescription drug pricing, rebates, fees, discounts, and other remuneration flowing among PBMs, pharmacies, drug manufacturers, and plan sponsors. It also requires PBMs to provide summary documents in plain language and machine-readable formats, including information that can help plan sponsors evaluate PBM services and help beneficiaries better understand their coverage.
The reporting requirements are extensive. They include drug-level and therapeutic-class-level data such as contracted compensation, net spending, out-of-pocket spending, rebate amounts, dispensing channel information, formulary placement rationales, and the impact of affiliated pharmacies or common ownership arrangements. For higher-spend drugs, the bill also requires information on comparable drugs in the same therapeutic class and any formulary changes from the prior year. In addition, the bill gives plan sponsors the right to request at least annual audits of PBMs, with access to records and related information needed to verify compliance and the accuracy of reported data.
If enacted, the bill would supplement New Jersey’s existing PBM law and impose new disclosure, reporting, and audit obligations on PBMs operating under contracts with health benefits plan sponsors. It would affect PBMs, plan sponsors, affiliated pharmacies, and related entities such as manufacturers, rebate aggregators, brokers, and consultants by requiring contract terms that support information sharing and compliance. The Department of Banking and Insurance would also gain authority to specify reporting formats, guidance, and certain definitions, including therapeutic class rationales and analogous compensation structures.
The bill’s overall tone is pro-transparency and pro-accountability, reflecting a policy goal of giving plan sponsors and beneficiaries clearer insight into drug spending and PBM practices. The text and available context do not show recorded votes or committee testimony, so there is no documented formal opposition or support in the provided materials. Based on the bill’s structure, it appears designed to address concerns about opaque pricing, rebate retention, and affiliated pharmacy steering.
The most likely points of contention are the breadth and burden of the disclosure requirements, the operational complexity of compiling claims-level and rebate-related data, and the audit provisions that require PBMs to open records to plan-selected auditors. Another likely issue is the treatment of affiliated pharmacies and common ownership arrangements, especially where the bill requires explanations of benefit designs that may steer prescriptions to mail-order, specialty, or retail channels. PBMs and related entities may view these provisions as intrusive or administratively costly, while plan sponsors and consumer advocates are likely to support them as necessary for transparency and cost control.